Paradigm Biopharmaceuticals Hits 50% Enrollment in Phase 3 Osteoarthritis Trial; Shares Up 4%
MT Newswires Live
Mar 31
Paradigm Biopharmaceuticals (ASX:PAR) achieved 50% enrollment in a phase 3 clinical trial of injectable pentosan polysulfate sodium for the potential treatment of osteoarthritis, according to a Tuesday filing with the Australian bourse.
The company said it has started dosing of the final participants required for inclusion in the interim analysis, with those results expected in August.
The study's primary endpoint is the change in weekly average of daily pain at day 112, while secondary endpoints include improvements in physical function, imaging-based structural outcomes, and safety assessments.
The company's shares gained nearly 4% in recent Tuesday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.